(a) As a laboratory, you must use the cutoff concentrations displayed in the following table for initial and confirmatory drug tests. All cutoff concentrations are expressed in nanograms per milliliter (ng/mL). The table follows:
| Initial test analyte |
Initial test cutoff concentration |
Confirmatory test analyte |
Confirmatory test cutoff concentration |
| Marijuana metabolites |
50 ng/mL |
THCA 1 |
15 ng/mL. |
| Cocaine metabolites |
150 ng/mL |
Benzoylecgonine |
100 ng/mL. |
| Opiate metabolites |
|
|
|
| Codeine/Morphine 2 |
2000 ng/mL |
Codeine |
2000 ng/mL. |
|
|
Morphine |
2000 ng/mL. |
| 6-Acetylmorphine |
10 ng/mL |
6-Acetylmorphine |
10 ng/mL. |
| Phencyclidine |
25 ng/mL |
Phencyclidine |
25 ng/mL. |
| Amphetamines 3 |
|
|
|
| AMP/MAMP 4 |
500 ng/mL |
Amphetamine |
250 ng/mL. |
|
|
Methamphetamine 5 |
250 ng/mL. |
| MDMA 6 |
500 ng/mL |
MDMA |
250 ng/mL. |
|
|
MDA 7 |
250 ng/mL. |
|
|
MDEA 8 |
250 ng/mL |
1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA).
2 Morphine is the target analyte for codeine/morphine testing.
3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
4 Methamphetamine is the target analyte for amphetamine/methamphetamine testing.
5 To be reported positive for methamphetamine, a specimen must also contain amphetamine at a concentration equal to or greater than 100 ng/mL.
6 Methylenedioxymethamphetamine (MDMA).
7 Methylenedioxyamphetamine (MDA).
8 Methylenedioxyethylamphetamine (MDEA).
(b) On an initial drug test, you must report a result below the cutoff concentration as negative. If the result is at or above the cutoff concentration, you must conduct a confirmation test.
(c) On a confirmation drug test, you must report a result below the cutoff concentration as negative and a result at or above the cutoff concentration as confirmed positive.
(d) You must report quantitative values for morphine or codeine at 15,000 ng/mL or above.
[65 FR 79526, Dec. 19, 2000, as amended at 75 FR 49862, Aug. 16, 2010; 77 FR 26473, May 4, 2012]